NDAINJECTIONINJECTABLE
Approved
Apr 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Estradurin (polyestradiol phosphate) is an injectable estrogen ester indicated for hormone replacement and estrogen-responsive conditions. It is administered via intramuscular injection and provides prolonged systemic estrogen exposure through slow hydrolysis of the phosphate ester prodrug.
LOE Approaching
With LOE approaching on this legacy 1957 product, commercial teams are likely small and focused on managed decline or niche patient retention rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Estradurin offers limited career growth potential given its LOE-approaching status and zero linked job postings. Roles here emphasize operational excellence, regulatory maintenance, and managed-care negotiations rather than market expansion or innovation.
Regulatory Affairs SpecialistSupply Chain Manager
Worked on ESTRADURIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.